Table 2.
Demographic data for each SVM diagnostic comparison: Mean (SD).
| Characteristic | UHR vs. HC | FEP vs. HC | FEP vs. UHR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HC (n = 19) | UHR (n = 19) | Analysis | HC (n = 19) | FEP (n = 19) | Analysis | UHR (n = 15) | FEP (n = 15) | Analysis | |
| Age (years) | 23.32 (3.43) | 22.42 (3.42) | 24.89 (4.41) | 24.37 (4.71) | 23.20 (3.43) | 23.27 (3.69) | |||
| Gender | 9M:10F | 9M:10F | 12M:7F | 12M:7F | 9M:6F | 9M:6F | |||
| WRAT estimated premorbid IQ | 107.58 (10.77) | 103.16 (13.14) | t = −1.22 | 108.53 (10.48) | 102.74 (9.33) | t = −1.68 | 104.87 (11.98) | 103.80 (9.97) | t = −0.25 |
| p = 0.237 | p = 0.110 | p = 0.807 | |||||||
| PANSS totala | 52.53 (9.28) | 54.37 (15.13) | 53.73 (9.11) | 51.80 (12.46) | t = −0.46 | ||||
| p = 0.655 | |||||||||
| PANSS positivea | 12.84 (3.67) | 12.58 (3.96) | 12.80 (3.65) | 12.07 (3.08) | t = −0.60 | ||||
| p = 0.556 | |||||||||
| PANSS negativea | 14.00 (4.08) | 13.79 (5.26) | 14.33 (4.05) | 13.47 (5.05) | t = −0.51 | ||||
| p = 0.618 | |||||||||
| PANSS generala | 25.68 (5.01) | 28.00 (8.35) | 26.60 (4.97) | 26.27 (7.35) | t = −0.14 | ||||
| p = 0.893 | |||||||||
| Total medicationb | 4538.49 (19226.27) | 32828.58 (29788.57) | 5748.75 (21628.90) | 31291.57 (27178.41) | |||||
| Mean medication/dayc | 13.27 (44.43) | 204.08 (116.35) | 16.81 (49.75) | 211.70 (109.89) | |||||
a
Symptom profile recorded at time of scan,
b
Total Medication refers to the average absolute amount of medication taken by that group in standardized mg units of Chlorpromazine ± 1SD,
c
Mean Medication/day is the average medication dosage taken by each subject during their period of treatment in standardized mg units of Chlorpromazine ± 1SD. UHR, Ultra-High Risk; FEP, first episode psychosis; HC, healthy subjects; M, males; F, females; WRAT, wide range achievement test; PANSS, positive and negative syndrome scale.